Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN)

Price 11,748.00p on 02-06-2023 at 17:04:29
Change 78.00p 0.67%
Buy 11,748.00p
Sell 11,744.00p
Buy / Sell AZN Shares
Last Trade: Unknown 170.00 at 11,572.824p
Day's Volume: 1,544,740
Last Close: 11,748.00p
Open: 11,636.00p
ISIN: GB0009895292
Day's Range 11,530.00p - 11,754.00p
52wk Range: 9,399.00p - 12,390.00p
Market Capitalisation: £182,077m
VWAP: 11,685.77171p
Shares in Issue: 1,550m

Recent Trades History Astrazeneca (AZN)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 170 11,572.824p Ordinary
Currency Conversion
OTC Trade
17:04:17 - 02-Jun-23
Unknown* 5 11,817.66444p Ordinary
Currency Conversion
OTC Trade
16:55:38 - 02-Jun-23
Unknown* 3 11,654.61293p Ordinary
Currency Conversion
OTC Trade
16:53:36 - 02-Jun-23
Unknown* 75 11,617.84817p Ordinary
Currency Conversion
OTC Trade
16:49:12 - 02-Jun-23
Unknown* 226 11,626.00p Ordinary
Currency Conversion
OTC Trade
16:44:23 - 02-Jun-23
Unknown* 881 11,642.076p Ordinary
Currency Conversion
OTC Trade
16:40:03 - 02-Jun-23
Unknown* 13,745 11,630.804p Ordinary
Currency Conversion
OTC Trade
16:40:03 - 02-Jun-23
Unknown* 140 11,746.236p Ordinary
Currency Conversion
OTC Trade
16:38:06 - 02-Jun-23
Unknown* 981 11,663.947p Ordinary
Currency Conversion
16:37:48 - 02-Jun-23
Unknown* 2,965 11,591.351p Ordinary
Currency Conversion
16:37:48 - 02-Jun-23

Share Price History for Astrazeneca

Time period:
to
Date Open High Low Close Volume

Share News for Astrazeneca

AstraZeneca sees positive results for Imfinzi in gastric cancers

2nd Jun 2023 18:04

(Alliance News) - AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers. Read More

TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval

1st Jun 2023 08:07

(Alliance News) - AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused brazikumab. Read More

TOP NEWS: AstraZeneca's Ultomiris wins another approval in Japan

26th May 2023 14:34

(Alliance News) - AstraZeneca PLC on Friday announced that its antibody complement inhibitor drug Ultomiris received another approval in Japan. Read More

AstraZeneca's Imfinzi plus Lynparza effective for endometrial cancer

26th May 2023 08:14

(Alliance News) - AstraZeneca PLC on Friday said that its most recent trial testing Imfinzi showed that the therapy significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy. Read More

LONDON BRIEFING: UK retail sales up; Hunt "comfortable" with recession

26th May 2023 07:57

(Alliance News) - Stocks in London are expected to kick off the final trading day of a fraught week with a minor gain, though US debt ceiling uncertainty continues to temper sentiment. Read More

FTSE 100 Latest
Value7,607.28
Change117.01

Login to your account

Forgot Password?

Not Registered